Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide in Adult Liver Transplant Recipients
NCT07125443Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
01
Overview
Open-label trial of nitric oxide in reperfusion injury (IRI), Vasoplegia and Post-reperfusion syndrome (PRS) (2 arms). Primary endpoints: Severity of post-reperfusion syndrome and Incidence of post-reperfusion vasoplegia. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
nitric oxide
03
Conditions
reperfusion injury (IRI)VasoplegiaPost-reperfusion syndrome (PRS)
Beyond the preview
Go deeper on NCT07125443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07125443.